Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets-Reference-Cited by-同舟云学术

Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets

Published:2015-04-22 Issue:3 Volume:8 Page:315-327
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Reikvam Håkon,Hoang Tuyen Thi van,Bruserud Øystein

Publisher

Informa UK Limited

Subject

Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1586/17474086.2015.1036025

Reference102 articles.

1. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

2. Targeted therapy in acute myeloid leukaemia: current status and future directions

3. The angioregulatory cytokine network in human acute myeloid leukemia – from leukemogenesis via remission induction to stem cell transplantation

4. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release

5. Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia;Cancers;2023-07-21

2. L20, a Calothrixin B analog, induces intrinsic apoptosis on HEL cells through ROS/γ-H2AX/p38 MAPK pathway;Biomedicine & Pharmacotherapy;2021-05

3. The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives;International Journal of Molecular Sciences;2020-09-17

4. Precision medicine for TP53-mutated acute myeloid leukemia;Expert Review of Precision Medicine and Drug Development;2019-07-30

5. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies;Expert Opinion on Drug Discovery;2017-07-27